Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Investigational Drug Treatment Study for Patients with Lung Cancer
This is the first study in humans for an investigational drug called CX-072. The purpose of this study is to look at the possible side effects, safety and tolerability of CX-072 when given alone or in combination with ipilimumab or vemurafenib and to find the highest tolerated dose of CX-072 taken safely alone or in combination with ipilimumab or vemurafenib. Ipilimumab is approved by the FDA for the treatment of melanoma. Vemurafenib is approved by the FDA for the treatment of melanoma with a specific change in its genes.
In order to participate you must meet the following criteria:
- Have metastatic or advanced unresectable tumors that progressed on standard therapy.
- Agree to provide mandatory archival tissue or fresh biopsy.
You will be excluded from the study if any of the following criteria apply to you:
- Have had prior therapy with a chimeric antigen receptor (CAR) T-cell containing regimen.
- Have a history of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.
- Have a history of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant.
This is a partial list of inclusion and exclusion criteria.